Bad Things Come In Threes At Viatris As Firm Issues Another Labelling Recall
Viatris Recalls Third Insulin Product This Year Over Missing Labels
Viatris has recalled a batch of its unbranded insulin glargine injector pens after a manufacturing error meant some pens might be missing labels. It is the third time this year the firm has had to recall an insulin product due to a labelling error.
You may also be interested in...
A further voluntary recall for Viatris’ insulin glargine biosimilar, this time for one of its recently launched interchangeable products, because of missing labels may draw unwanted interest from the US FDA, a leading analyst has warned.
Viatris has voluntarily recalled one batch of its Semglee (insulin glargine) pre-filled pens due to the potential for the label to be missing on some pre-filled pens within a labelled carton. The company said that it will arrange for the return of all recalled products.
The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines.